+34 9340006100 -ext. 437807-info@nanbiosis.com

Nanbiosis

You are here : Home / Archive for "biomarker"

U2. Custom Antibody Service Unit (CAbS)

U2 CAbS-hybridoma clone
Ciber bbn

U2. Custom Antibody Service (CAbS)

  • Scientific Director: Prof. Pilar Marco pilar.marco@cid.csic.es
  • Scientific Coordinator: Dra. Nuria Pascual npdqob@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC

IQAC CSIC

Order request
U2 CAbS-Monoclonal antibody developmentU2 CAbS-Monoclonal antibody development
U2 CAbS-Hapten synthesisU2 CAbS-Hapten synthesis
U2 CAbS-Antibody purificationU2 CAbS-Antibody purification

Description

The facility is located in the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC; Barcelona). It is equipped with a laboratory for the development and production of monoclonal antibodies. The laboratory is fully equipped for obtaining, selecting and storing monoclonal antibody producing hybridomas. In addition, the facility has infrastructure for the production of polyclonal antibodies, as well as laboratories for the synthesis of bioconjugates, haptens, the purification of antibodies and the performance of immunoassays. In addition to the above mentioned equipment, the IQAC-CSIC provides animal husbandry facilities and a unit for the synthesis of organic molecules.

The equipment consists in an inverted phase contrast microscope with a camera, two Class II laminar flow biological safety cabinets, two CO2 incubators, a bioreactor for hybridoma culture, and tangential filtration unit for purification of the antibodies produced in the culture. Among the items of available equipment it should be highlighted a spotter for selection of high antibody producing cell lines and an automated ELISA microplate washer an ELISA reader, two AKTA Prime Liquid chromatography systems for antibody purification, plus standard equipment (centrifuges, fridges, liquid nitrogen containers, autoclave, baths, and vacuum equipment) and all the necessary routine laboratory apparatus.Cabs also has access to a fully equipped chemistry laboratory for the synthesis of haptens and immunoreagents.

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U2. Services & Rates

Equipments

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
PIE1400061 Molecular links between diabetes and neurodegenerative diseases ISCIII Oberver
2014SGR1484 Consolidated Research Group Generalitat de Catalunya Participant
FP7-614168 Real time monitoring of SEA contaminants by an autonomous Lab-on-a-Chip biosensor (SEA-on-a-CHIP) European Commission Oberver
CI16-00031 Caixa Impulse A new approach for the detection of Pseudomonas aeruginosa CaixaBank Participant
MSCA-ITN2015-675412 New Diagnostics for Infectious Diseases European Commission Participant
TECCTP15-1-0011 Ajuda acreditació Tecnio del grup Nb4D ACCIÓ: Generalitat de Catalunya Others

Publications


2016

  • Roncador G., Engel P., Maestre L., Anderson A.P., Cordell J.L., Cragg M.S. et al. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. 2016;8(1):27-36.
  • Pastells C., Pascual N., Sanchez-Baeza F., Marco M.-P.. Immunochemical Determination of Pyocyanin and 1-Hydroxyphenazine as Potential Biomarkers of Pseudomonas aeruginosa Infections. Analytical Chemistry. 2016;88(3):1631-1638.
  • Salvador J.-P., Marco M.-P.. Amperometric Biosensor for Continuous Monitoring Irgarol 1051 in Sea Water. Electroanalysis. 2016;28(8):1833-1838.

News U2

15 May

New look of Nb4D – CAbS (NANBIOSIS U2) “Revolutionising Diagnosis”

Nb4D has a new look on line! Nb4D Group (of IQAC-CSIC and CIBER-BBN) has lunched a new website “Revolutionsising Diagnosis“ with the aim to facilitate a faster and easier navigation througth their “pioneering research to develop new diagnostic and therapeutic approaches” and their solutions and expertise to help researchers and companies. Antibodies, bioreceptors, hapten design and synthesis, immunoanalytical method development, new ivd tools, surface functionalization, therapeutic antibodies and much more knowledge and expertise revolutionising diagnosis. The new website contains a page for CAbS-NANBIOSIS. Custom Antibody Service (CAbS), unit 2 of the ICTS NANBIOSIS[...]

28 Feb

Rare diseases international day 2023: some NANBIOSIS contributions

Today is the international day of rare diseases, a day to raise awareness and instigate change for people living with a rare disease. From NANBIOSIS we want to sume to this celebration and higtligh our commitment to helping people with rare diseases through research. Dr. Ibane Abasolo, Scientific Director of NANBIOSIS U20, was at the WORLDSymposia conference last week in Orlando (FL, USA), where the latest advances in preclinical study and clinic of lysosomal storage diseases were explained. There, she presented the results obtained in the Smart4Fabry project coordinated by the CIBER-BBN where nanoliposomes were developed for the treatment of[...]

27 Feb

New method for the detection of RNA viruses such as SARS-CoV-2

Several CIBER-BBN groups at the University of Barcelona, the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC) and the Institute of Nanoscience and Materials of Aragon (INMA) —a joint institute of the CSIC and the University of Zaragoza (UNIZAR)— have developed a new method for detecting RNA viruses based on the technology of using probes that form triplex structures. This innovative methodology opens up new options to detect viruses such as SARS-CoV-2, the influenza A (H1N1) virus or the respiratory syncytial virus (RSV), a pathogen that affects newborns and requires differential diagnostic care. This[...]

15 Nov

Happy Day of Chemistry! The role of Chemistry in a sustainable research in health

Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]

19 Oct

The first TECNIO Conference and NANBIOSIS’ researchers participation

More than 200 people attended the first edition of the TECNIO Conference that took place on October 19th, 2022 in Girona. Outstanding experts from research groups, companies and the Catalan administration discussed the model of technological sovereignty that Catalonia needs to generate high-impact innovation. As far as Nora Ventosa, President of the TECNIO Association and Scientific Director of NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit (from CIBER-BBN and IQAC): “Political management is the key to ensure that the path of transference follows a high speed train” Researchers of NANBIOSIS U2 Custom Antibody Service (CAbS) – Nb4D Group from CIBER-BBN and[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

28 Dec

New results evidence new biomarkers for early diagnosis of P. aeruginosa infections

Pseudomonas aeruginosa is a common multidrug-resistant pathogen that causes acute and chronic infections. However, P. aeruginosa, as many other bacterial species, has developed resistance to antibiotics being difficult to treat. For this reason diagnostic methods allowing detection at early  stages of the infection are required  and, therefore, efficient biomarkers of infection are very helpful. These fast diagnosis will help on the subsequent therapeutic treatment. The Nb4D group of CIBER-BBN and IQAC-CSIC (led by M.-Pilar Marco) has recently conducted a research to develop a highly sensitive, specific and reliable immunochemical assay to detect pyocyanin (PYO), one of the most important virulence factors[...]

01 Dec

Nanomedicine in the Medicine of the Future

Scientists of CIBER-BBN and NANBIOSIS ICTS have participated in the 4th Conference “Anticipating the Medicine of the Future”, which took place on November 30th, organized by the Roche Institute Foundation. The topics for this ediction had been identified by the Observatory of Trends in the Medicine of the Future: Pharmacogenomics, Nanomedicine and Epigenomic The event counted with three roundtables for discussion in relation to the three topics. The second one, on Nanomedicine, was moderated by Joaquín Arenas, Director of the Research Institute of the 12 de Octubre University Hospital. Ramón Martínez Máñez, Professor of Inorganic Chemistry at the Interuniversity Researc[...]

U2-Custom Antibody Service (CAbS)
• Read More

U25. NMR: Biomedical Applications I

Ciber bbn

U25. NMR: Biomedical Applications I

  • Scientific Director: Prof. Carles Arús Carles.Arus@uab.es
  • Scientific Coordinator: Ana Paula Candiota AnaPaula.Candiota@uab.cat
  • Entities: Servicio de Resonancia Magnética Nuclear (SeRMN) & Institut de Biotecnología i Biomedicina (IBB) & Universidad Autónoma de Barcelona (UAB)
  • Address: Facultad de Ciencias, Edificio C, 08193, Cerdanyola del Vallés, Barcelona, Spain
  • Phone: +34 935 814 126
  • Web: GABRMN-UAB seRMN-UAB

UAB

Order request
U25 RMN- Representative time-course 13C spectra of a GL261U25 RMN- Representative time-course 13C spectra of a GL261
U25 RMN Biomedical Applications -scannerU25 RMN Biomedical Applications -scanner
U25 RMN brain tumour modelU25 RMN brain tumour model

Description

The platform is divided between the Servei de Ressonància Magnètica Nuclear (Nuclear Magnetic Resonance Facility) (SeRMN) (http://sermn.uab.cat/) and the Institut de Biotecnologia i Biomedicina (IBB) for bioinformatics applications of the UAB . This platform is coordinated by Prof. Carles Arús, PI of the Nuclear Magnetic Resonance Biomedical Applications Group (GABRMN) (http://gabrmn.uab.es/), with a recognized research track record in the use of NMR as a tool for biomedical applications, and more especifically to identify biomarkers of different pathologies. The main objective of the Platform of Biomedical Applications of Nuclear Magnetic Resonance at the Universitat Autònoma de Barcelona (UAB) is the acquisition, processing and/or interpretation of Nuclear Magnetic Resonance data.

The platform is equipped with 10 spectrometers operating at magnetic fields between 5.8 and 14.1 Teslas (T), including a MRI scanner, Bruker BioSpec, equipped with a 7T horizontal magnet for preclinical trials.

The unit also hosts a computational platform at the IBB, with a total storage capacity of 12TB, which is accessible through the UAB network. The computational platform also hosts two multicentre databases (INTERPRET and eTUMOUR), with NMR and clinical data for more than 1000 human brain tumour patients.

The uniqueness in this case lies in access, in the same location, equipment for NMR studies in vivo, ex vivo and in vitro, molecular imaging accessories by using polarization as well as fixed metabolomic patterns. This configuration allows to validate results of molecular imaging in vivo with other in vitro facilities.

Services

 

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U25. Services & Rates

Equipments

In addition to the indicated equipment, it has:

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Publications

2016

  • Delgado-Goni T., Ortega-Martorell S., Ciezka M., Olier I., Candiota A.P., Julia-Sape M. et al. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis. NMR in Biomedicine. 2016;:-.
  • Cordon-Barris L., Pascual-Guiral S., Yang S., Gimenez-Llort L., Lope-Piedrafita S., Niemeyer C. et al. Mutation of the 3-phosphoinositide-dependent protein kinase 1 (PDK1) substrate-docking site in the developing brain causes microcephaly with abnormal brain morphogenesis independently of akt, leading to impaired cognition and disruptive behaviors. Molecular and Cellular Biology. 2016;36(23):2967-2982.
  • Ferrer-Font L., Alcaraz E., Plana M., Candiota A.P., Itarte E., Arus C.. Protein Kinase CK2 Content in GL261 Mouse Glioblastoma. Pathology and Oncology Research. 2016;:-.
  • Ciezka M., Acosta M., Herranz C., Canals J.M., Pumarola M., Candiota A.P. et al. Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation. Journal of Neuro-Oncology. 2016;:1-10.

News U25

20 Mar

Nanoparticles to modulate topography and ligand distribution at the nanoscale: impact on cell behavior

Doctor Marc Martínez from the Nanomol-Bio group – NANBIOSIS U6 from CIBER-BBN at ICMAB-CSIC, defended his PhD thesis “Nanoparticles to modulate topography and ligand distribution at the nanoscale: impact on cell behavior” on 9 March 2023 at ICMAB. he PhD thesis was supervised by Imma Ratera, Judith Guasch and Nora Ventosa from the Nanomol-Bio group at ICMAB-CSIC. Ana Paula Candiota Silveira, Scientific Coordinator of NANBIOSIS U25 was part of the Committee that evaluated the Thesis tooghether with Jesús Martínez de la Fuente, Instituto de Nanociencia y Materiales de Aragón (INMA-CSIC) (President),  and Anna Lagunas Targarona, Institut de Bioenginyeria de Catalunya (IBEC) (Vocal). As[...]

07 Sep

Philipps-Universität Marburg (Germany) -NANBIOSIS U25 collaboration on the study of tumour microenvironment (TME) changes in Glioblastoma

The scientific coordinator of NANBIOSIS U25 “RNM: Biomedical Application I”, Ana Paula Candiota, was recently awarded with a mobility fellowship from CIBER-BBN for a scientific exchange visit to Philipps-Universität Marburg, in Marburg, Germany. This scientific stage was motivated for a sustained collaboration between the research groups (GABRMN, in charge of U25 and Neurosurgery Lab group in Marburg), regarding the study of tumour microenvironment (TME) changes in Glioblastoma and possible relationship with the noninvasive MRSI-based biomarkers. Both groups have applied together to different funding calls including ERA-NET Transcan and Pathfinder Open, and Marburg group has hosted a predoctoral stage from a[...]

16 Aug

Two NANBIOSIS Units of CIBER-BBN at UAB, one of the 300 best universities in the world, according the Shanghai Ranking

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the Autonomous University of Barcelona among the elite of the 300 best universities in the world. This indicator organizes up to 20,000 university centers worldwide,based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings Two of NANBIOSIS Units created by UAB and CIBER-BBN are part of this university: U1 Protein Production Platform (PPP), led by Toni Villaverde, Neus Ferrer and Mercedes Marquez, offer an “tailored” service for the design,[...]

05 Jul

Metal-free contrast agents: novel approaches

The joint expertise of CIBER-BBN Nanomol Group – NANBIOSIS U6 from at ICMAB-CSIC (José Vidal and Vega Lloveras) and NANBIOSIS U25 at UAB (Ana Paula Candiota), led to a recently published article in the prestigious journal Biomacromolecules Brain tumours such as Glioblastomas are a challenge in the clinics and proper diagnosis and follow-up are crucial for patient outcome. Contrast agents are usually administered to patients for assessing blood brain barrier integrity and quantitation of enhancing areas are part of the clinical criteria for estimating response/relapse. However, most contrast agents currently used in clinics are based in metal elements such as[...]

10 May

Improving quality of MR spectra from mouse brain. MRSI-detected pattern in glioblastoma patients

Work performed at Unit 25 of Nanbiosis ICTS of “NMR: Biomedical ApplicationsI” is being shown at the Joint annual meeting ISMRM-ESMRMB (May 7-12th) London, with the participation of CIBER-BBN group members Ana Paula Candiota, Silvia Lope-Piedrafita, Miquel Cabañas (abstract 1), Carles Arús, Gulnur Ungan, Margarida Julià-Sapé, Alfredo Vellido and Carles Majós (abstract 2). In the first abstract, entitled “High resolution Multi-voxel spectroscopy using CSI-semi-LASER for mouse brain preclinical studies” we focused into improving quality of MR spectra obtained from mouse brain, a key factor when trying to pursue metabolomic-based biomarkers. The second abstract, entitled “MRSI-detected pattern in glioblastoma patients on[...]

06 Apr

Targeting of the breast cancer stem cells to improve the treatment of triple negative breast cancer

On April 1st PhD candidate Patricia Cámara Sánchez defended her doctoral thesis entitled “Targeting of the breast cancer stem cells to improve the treatment of triple negative breast cancer“, where ICTS-Nanbiosis Unit 20 participated in the in vivo assays. The thesis was supervised by Dr. Ibane Abasolo  (scientific director of Unit 20 from CIBER-BBN and VHIR). Nanbiosis was also present within the jury, with Dr. Ana Paula Candiota (scientific coordinator of Unit 25 from CIBER-BBN and UAB) acting as secretary. Patricia Cámara graduated as biochemist, did the master’s degree in Translational Biomedical Research from VHIR-UAB. Shortly after, started the PhD, which was aimed[...]

19 Jul

Radical Dendrimers as Contrast Agents for Magnetic Resonance Imaging

José Vidal Gancedo, researcher from ICMAB-CSIC and CIBER-BBN is leading the project VIRADEN: “In vivo Studies of Radical Dendrimers as Contrast Agents for Magnetic Resonance Imaging“, one of the ICMAB Frontier Interdisciplinary Projects (FIP) 2021. The project aims to evaluate the new contrast agents for MRI based on organic radical dendrimers developed in his group, to substitute the currently used contrast agents based on toxic metals, with the final goal of obtaining useful contrast agents in the early detection of tumors José Vidal has explained NANBIOSIS participation in the project through Biomaterial Processing and Nanostructuring equipments of NANBIOSIS U6 counting wit[...]

03 Jun

Novel nano-encapsulation approach for efficient dopamine delivery in Parkinson’s treatment

UAB Parkinson’s disease (PD) is a common neurodegenerative disorder caused by the death of dopaminergic neurons in a part of the brain (known as substantia nigra pars compacta), which leads to a deficit of dopamine (DA), one of the main neurotransmitters active in the central nervous system. Symptomatic treatment focuses on increasing the concentration of dopamine into the brain.However, dopamine is not directly administered, because it is unable to cross the so called blood-brain barrier, which prevents some of the substances circulating in the blood to penetrate into the nervous system. Thus, DA precursor levodopa (L-DOPA) –an amino-acid which participates[...]

U25-NMR Biomedical Applications I
• Read More

U26. NMR: Biomedical Applications II

Ciber bbn

U26. NMR: Biomedical Applications II

  • Scientific Director: Prof. Ramon Martinez Máñez  rmaez@qim.upv.es
  • Scientific Coordinator: Dr. Salvador Gil salvador.gil@uv.es
  • Entities: Universitat de Valencia (UV)
  • Address: C/Dr. Moliner, 50, Edificico Investigación, 1º Pl., 46100, Valencia, Spain
  • Phone: +34 963877343
  • Tel Prof. Martínez: +34 963877343 ; Tel Dr. Gil : +34 963543135
  • Web: UV

UV

Order request
U26. Sample preparation labU26. Sample preparation lab
U26. DRX-600 Bruker NM R equipment (14T) with autosamplerU26. DRX-600 Bruker NM R equipment (14T) with autosampler
U26. DRX-600 Bruker NM R equipment (14T) with refrigerated autosamplerU26. DRX-600 Bruker NM R equipment (14T) with refrigerated autosampler

Description

Located in the Faculty of Medicine of the University of Valencia (UV) has a laboratory with a NMR (14T) for acquiring unique metabolic profiles of biofluids, cell lines and tissues. This Unit is coordinated by Dr. Ramón Martínez Máñez, PI of the Applied Molecular Chemistry Group of the Universidad Politécnica de Valencia, together with Dr. Salvador Gil, Director of the Central Service for Experimental Research (SCSIE).

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U26. Services & Rates

Equipments

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
MAT2015-64139-C4-1-R INTELLIGENT NANOMATERIALS, PROBES AND DEVICES FOR THE INTEGRATED DEVELOPMENT OF NEW TOOLS APPLIED TO THE BIOMEDICAL FIELD MINISTERIO DE ECONOMIA INDUSTRIA Y COMPETITIVIDAD Participant
MAT2015-64139-C4-C-R CHROMOGENIC AND FLUOROGENIC CHEMOSENSES FOR THE DETECTION OF NEUROTRANSMITTERS MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD Participant
PROMETEOII/2014/047 New approaches for the design of controlled release materials and the detection of dangerous compounds Generalitat Valenciana Participant
AP2012-1478 HELP CONV FPU 2012 - DE LA TORRE PAREDES, CRISTINA Ministerio de Educacion, cultura y deporte Participant
MAT2012-38429-C04-01 Development of functionalized materials with nanoscopic doors for controlled release applications and sensors for the detection of ammonium nitrate, sulfuric acid and CO Ministerio de Economia y Competitividad Participant
UPV-FE-16-A1 CONSTITUTION OF A SMART DRUG DISCOVERY PLATFORM Participant
UPV-FE-15-A2 Development of nanomaterials and sensors for early and non-invasive diagnosis and prognosis UNIVERSIDAD POLITECNICA DE VALENCIA Participant
AP2013-06017 HELP CONTRACT FPU 2013-SANCHEZ CABEZAS MInisterio de Educacion, Cultura y Deporte Participant

Publications

2016

  • Rosales A.M., Aznar E., Coll C., Garcia Mendoza R.A., Lorena Urbano Bojorge A., Gonzalez N.F. et al. Study of the dependency of the specific power absorption rate on several characteristics of the excitation magnetic signal when irradiating a SPION-containing ferrofluid. Journal of Magnetics. 2016;21(3):460-467.

News U26

25 Oct

Ramón Martínez Máñez, Scientific Director of NANBIOSIS U26 obtains an ERC Advanced Grant

Ramón Martínez Máñez, researcher at the Polytechnic University of Valencia (UPV) and scientific director of the Bioengineering, Biomaterials and Nanomedicine area of ​​the CIBER (CIBER-BBN) and NANBIOSIS U26, has obtained an ERC Advanced Grant –the most prestigious grant from the European Research Council– endowed with 2.5 million euros for the development of the EDISON project (Engineered Particles for Chemical Communication). This project focuses on the field of chemical or molecular communication. Its objective is the study, development and application of nanoparticles that are capable of communicating with each other and whose application would represent a revolution in the field of[...]

16 Aug

The University of Valencia among the 300 best universities in the world, hosting NANBIOSIS U26 of CIBER-BBN on RNM for Biomedical Applications

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the University of Valencia among the elite of the 300 best universities in the world and the second of the Spanish universities. This indicator organizes up to 20,000 university centers worldwide,based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings The NANBIOSIS U26 NMR: Biomedical Applications II created by CIBER-BBN is hosted by the University of Valencia is led by Prof. Ramón Martínez Ma´ñez and Prof Salvador Gil Grau[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

29 Mar

Is it possible to communicate microorganisms from different kingdoms? Yes, it is, using “Nanotranslators”

CIBER, March 28 2022 Researchers from the Polytechnic University of Valencia (UPV) and the CIBER-BBN has demonstrated, for the first time, the potential of using “translator” nanoparticles to facilitate communication between different types of cells or microorganisms. His study could have application in multiple fields, especially in the medical field for the prevention and treatment of cancer. “We have shown that it is possible to communicate microorganisms from different kingdoms using nanoparticles as translators. The nanoparticles process a message produced by the first type of cells (bacteria) and transform it into an understandable message for the second type of cells[...]

01 Dec

Nanomedicine in the Medicine of the Future

Scientists of CIBER-BBN and NANBIOSIS ICTS have participated in the 4th Conference “Anticipating the Medicine of the Future”, which took place on November 30th, organized by the Roche Institute Foundation. The topics for this ediction had been identified by the Observatory of Trends in the Medicine of the Future: Pharmacogenomics, Nanomedicine and Epigenomic The event counted with three roundtables for discussion in relation to the three topics. The second one, on Nanomedicine, was moderated by Joaquín Arenas, Director of the Research Institute of the 12 de Octubre University Hospital. Ramón Martínez Máñez, Professor of Inorganic Chemistry at the Interuniversity Researc[...]

27 May

New device for more efficient gluten detection

About 1% of the world’s population suffers from celiac disease, a complex and autoimmune disorder caused by ingestion of gluten and for which there is no treatment beyond its elimination from the diet. In Spain every May 27, the National Celiac Day is commemorated to publicize the disease and give visibility and support to people with celiac disease. The detection of gluten becomes a key element for celiac patients to control the disease, as well as for the food industry, whose regulation requires declaring its presence in food. In this line, a team of researchers coordinated by the professor of[...]

21 May

A new biosensor will help for the early diagnosis of breast cancer

A team of Spanish researchers coordinated by the professor of the Polytechnic University of Valencia (UPV) and scientific director of the CIBER-BBN and NANBIOSIS unit 26, Ramón Martínez Máñez, and the Valencian oncologist, co-coordinator of the Research Group of Biology in Breast Cancer of the INCLIVA Health Research Institute, of the Hospital Clínico de València, Ana Lluch, also belonging to the CIBER de Cáncer (CIBERONC), has developed a prototype of a new biosensor to help detect breast cancer in its phases earlier. The work has been published in ACS Sensors magazine. According to the latest data collected by the European[...]

20 Apr

Elena Aznar Gimeno (NANBIOSIS U26) leads a CIBER-BBN transfer project.

The CIBER-BBN transfer program, with its call for transfer projects, has selected two projects for next year with the aim of promoting the transfer of scientific or technological results, derived from the research carried out by the CIBER-BBN groups, to the industrial sector. One of these projects selected is directed by Elena Aznar Gimeno, researcher from the group led by Ramon Martínez Máñez at the IDM-Polytechnic University of Valencia, together with an external group led by Javier Pemán García, from the La Fe Health Research Institute From Valencia. The project has been jointly financed by CIBER-BBN and a company interested[...]

U26-NMR Biomedical Applications II
• Read More

U28. NanoImaging Unit

Bionand

U28. NanoImaging Unit

    • Scientific Director: Dr. Mª Luisa García Martín mlgarcia@ibima.eu
    • Scientific Coordinator: Mónica Feijóo Cuaresma mfeijoo@ibima.eu
    • Entities: Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND)
    • Address: C/Severo Ochoa 35, 29590, Málaga, Spain
    • Phone: +34 952 367 600
    • Web: IBIMA-Plataforma BIONAND

Junta de Anadalucía Universidad de Málaga

Order request

Description

The Nanoimaging Unit is located in Malaga at the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), and it has been conceived and optimized to provide very diverse and integrated technological support for nanotechnology-based biomedical research, offering advanced services to internal and external users. This facility is coordinated by Dr Mª Luisa García Martín, who has wide expertise in the field of Magnetic Resonance Imaging and Spectroscopy applied to biomedical research.

The Unit brings together a wide range of cutting-edge technologies, and it is divided into four departments, each with a dedicated specialist:

– Small Animal Multimodal Imaging: Small animal (pre-clinical) imaging is a vital tool in biomedical research that allows biological processes and potential medicines to be studied in animal models using non-invasive methods. This department offers some of the most relevant pre-clinical imaging modalities, namely, MRI, in vivo Bioluminescence and Fluorescence Imaging, and micro-CT. These techniques are essential for preclinical evaluation and characterization of new diagnostic and therapeutic agents. The combined use of these technologies and new highly specific imaging probes are the basis of molecular imaging.

– Magnetic Resonance (NMR): it is equipped with two High-resolution NMR Spectrometers: a 400MHz NMR spectrometer for routine experiments and a higher field, 600 MHz, spectrometer dedicated to high-resolution magic angle spinning (HR-MAS) NMR and in vitro studies that are very demanding in terms of sensitivity. It also has a TD-NMR analyzer for relaxivity measurements in the clinical field (1.44 T).

– Electron Microscopy: It offers access to transmission electron microscopy (TEM), Cryo-TEM and Electron Tomography, high-resolution scanning electron microscopy (SEM) and environmental SEM. A special emphasis has been made on high-end sample preparation techniques through cryo-immobilization. All the equipment has been configured to provide its best on biological and nanomedicine applications. TEM, SEM and sample preparation facilities and services are offered to provide structural characterizations at the micro and nano scales. Biological and medical applications are the main objective of this equipment but are not limited to them. Any other scientific and engineering field can take advantage of them due to their versatility for public and private research, quality control, failure analysis, etc.

– Advanced Fluorescence: It hosts an excellent range of facilities capable of supporting high-quality biomedical research. These applications can range from the initial characterization of the fluorescent properties of novel nano-compounds to the evaluation of their medical applications using tissue culture and animal models. In addition, the range of possible applications goes far beyond nanomedicine to include the characterization of patient tissues, preclinical studies using rodent models, small-scale drug screening and studies using model organisms such as Zebrafish or Drosophila Melanogaster. The service is operated in close collaboration with the other advanced facilities of the Nanoimaging Unit, and the other units of Bionand, to ensure that researchers can easily combine fluorescence-based techniques with other complementary approaches such as Electron microscopy or Nuclear Magnetic Resonance.

Moreover, the location of the NanoImaging Unit allows it to be linked to other complementary Units available at BIONAND, such as the Cell Culture Unit (containment levels 1 and 2), the Chemical Unit (it offers a wide range of equipment and techniques in which materials and their interaction with biological samples can be characterized), the Animal House (rat, mouse and zebrafish accommodation), and the Histology Unit (it also offers Cutting/grinding based histological sectioning for hard tissues or other materials unsuitable to be sectioned by routine methods)

Services

In addition to the services within the NanoImaging Unit, the following specialised services are offered:

– Cutting/grinding based histological sectioning (Onsite&Remote) OUTSTANDING: This technique is recommended for obtaining histological samples from hard tissues or other materials unsuitable to be sectioned by routine methods, e.g. undecalcified bone tissue, metallic or ceramic implants, or samples that combine hard and soft components. With the EXAKT system, 10-15 μm slices can be made without disrupting the interface between areas of different hardnesses. Applications: Processing and fixation of fresh samples, Dehydration, plastic infiltration and polymerization, Cutting of blocks to obtain surfaces of interest, Block grinding, and Histological staining.

– Animal Housing (Onsite&Remote): The BIONAND Animal Facility Service is a research support service that aims to house experimental animals: zebrafish, rats and mice, and provide the facilities, materials, equipment and expertise needed to conduct pre-clinical trials based on the technologies and products developed in Centre from both research groups and companies

U28. Services & Rates

Equipments

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
T96 BIOMEDICAL SIGNAL INTERPRETATION & COMPUTATIONAL SIMULATION DGA Participant
UZCUD2016-TEC-03 Optimization of a submersible device for the monitoring of the photoplestimográfica signal CUD Participant
DPI2016-75458-R MULTI-SCALE PHYSIOLOGY-DRIVEN COMPUTATIONAL TOOLS TO ASSIST IN THE ASSESSMENT AND MANAGEMENT OF CARDIAC DYSFUNCTIONS MINECO Participant
TIN2013-41998-R THE AUTONOMOUS NERVOUS SYSTEM AS A MODULATOR OF CARDIAC FUNCTION: INTEGRAL RESEARCH THROUGH SIGNAL PROCESSING AND COMPUTATIONAL MODELING MINECO Participant

Publications

2016

  • Laguna P., Martinez Cortes J.P., Pueyo E.. Techniques for Ventricular Repolarization Instability Assessment from the ECG. Proceedings of the IEEE. 2016;104(2):392-415.
  • Pueyo E., Dangerfield C.E., Britton O.J., Virag L., Kistamas K., Szentandrassy N. et al. Experimentally-based computational investigation into beat-to-beat variability in ventricular repolarization and its response to ionic current inhibition. PLoS ONE. 2016;11(3):-.
  • Romero D., Martinez J.P., Laguna P., Pueyo E.. Ischemia detection from morphological QRS angle changes. Physiological Measurement. 2016;37(7):1004-1023.
  • Vicente J., Laguna P., Bartra A., Bailon R.. Drowsiness detection using heart rate variability. Medical and Biological Engineering and Computing. 2016;:1-11.
  • Alcaine A., De Groot N.M.S., Laguna P., Martinez J.P., Houben R.P.M.. Spatiotemporal model-based estimation of high-density atrial fibrillation activation maps. Digital Signal Processing: A Review Journal. 2016;54:64-74.
  • Bolea J., Pueyo E., Orini M., Bailon R.. Influence of heart rate in non-linear HRV indices as a sampling rate effect evaluated on supine and standing. Frontiers in Physiology. 2016;7(NOV):-.
  • Ortigosa N., Rodriguez-Lopez M., Bailon R., Sarvari S.I., Sitges M., Gratacos E. et al. Heart morphology differences induced by intrauterine growth restriction and preterm birth were measured on the ECG at preadolescent age. Journal of Electrocardiology. 2016;:-.
  • Hernando A., Lazaro J., Gil E., Arza A., Garzon J.M., Lopez-Anton R. et al. Inclusion of Respiratory Frequency Information in Heart Rate Variability Analysis for Stress Assessment. IEEE Journal of Biomedical and Health Informatics. 2016;20(4):1016-1025.

U28. NanoImaging Unit
• Read More

U29. Oligonucleotide Synthesis Platform (OSP)

U2 CAbS-hybridoma clone
Ciber bbn

U29. Oligonucleotide Synthesis Platform (OSP)

  • Scientific Director: Prof. Ramon Eritja: recgma@cid.csic.es
  • Scientific Coordinator: Dr. Anna Aviñó: aaagma@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC), Spanish National Research Council (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 145
  • Web: IQAC- CSIC
IQAC CSIC
Order request
U29 OSO. jpgU29 OSO. jpg
U29 (OSP)U29 (OSP)
U29.-Oligonucleotide-Synthesis-PlatformU29.-Oligonucleotide-Synthesis-Platform

Description

This unit is coordinated by the Nucleic Acids Chemistry Group at the Institute for Advanced Chemistry of Catalonia (IQAC), Spanish National Research Council (CSIC) and has the equipment needed for the production of oligonucleotides at low scale (mg to mg), purification, characterization and post-synthesis modification. The service counts with laboratories for synthesis and modification of oligonucleotides including DNA/RNA synthesizer, analytical and semi-preparative HPLC equipment for the purification and characterization of oligonucleotides. The service will focus in providing expert opinion to researchers as well as the production of tailored oligonucleotides. Routine synthesis of oligonucleotides used as primers will not be produced as there is a large number of commercial sources that provide a quick and low price service. The oligonucleotide synthesis platform will focus in providing modified oligonucleotides (ONs) that are difficult to obtain from commercial sources. These include microgram to milligram amounts of DNA and RNA derivatives carrying several modifications as well as oligonucleotide conjugates carrying lipids, membrane-receptors ligands, carbohydrates and peptides designed for therapeutic or diagnostic purposes. The facility benefits from the wide experience of Prof. Ramon Eritja that has more than 30 years expertise in the development of modified oligonucleotides.

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE
U29. Services & Rates

Equipments

Active projects

RefTitleFundin OrganismRole
CTQ2017-84415-R STUDY OF ADN STRUCTURES WITH BIOMEDICAL POTENTIALMINECOCoordinator

Other projects

RefTitleFundin OrganismRole
SBPLY/17/180501/000376Development and validation of new intelligent administration systems of RNAs in the injured spinal cord: application in a neuroprotective therapy based on miR-138Junta de Castilla-La Mancha Participant
BIO2017-92113-EXP New tailored microRNA-based antifungal agents for crop protectionMINECO - Explora-Participant
CA17103CA17103 Delivery of antisense RNA therapeutics (DARTER) C.C.E.E. COST Action Participant
AC18/00046Monitoring of Acquired Brain Injury and recovery of biomarkers by the combined label-free NanoSensing of multiple circulating molecules (ABISens).Euronanomed-III (ERA-Net cofund action on Nanomedicine)Participant
CSIC-COV19-041Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV) Consejo Superior de Investigaciones Científicas (CSIC)Participant
Prometeo/2020/081Use of microRNA modulators as experimental therapies in type 1 myotonic dystrophy Generalitat Valenciana Participant

Publications

2019

“Synthesis of oligonucleotides carrying nucleic acid derivatives of biomedical and structural interest” Eritja, R., Aviñó, A., Fàbrega, C., Alagia, A., Jorge, A.F., Grijalvo, S. In “Enzymatic and chemical synthesis of nucleic acid derivatives” (Fernández Lucas and Camarasa Eds) Willey-VCH Verlag, Weinheim (Germany), pp 237-258, (2019).

Cationic niosomes as non-viral vehicles for nucleic acids. Challenges and opportunities in gene delivery. Grijalvo, S., Puras, G., Zárate, J., Sainz-Ramos, M., AL Qtaish, N., López, T., Mashal, M., Attia, N., Díaz Díaz, D., Pons, R., Fernández, E., Pedraz, J.L., Eritja, R.  Pharmaceutics, 11(2), 50 (2019).

“Parallel clamps and polypurine hairpins (PPRH) for gene silencing and triplex-affinity capture: design, synthesis and use” Aviñó, A., Eritja, R., Cuidad, C., Noe, V. Current Protocols on Nucleic Acid Chemistry, e78 (2019).

“Efficient bioactive oligonucleotide-protein conjugation for cell-targeted cancer therapy” Aviñó, A., Unzueta, U., Cespedes, M.V., Casanova, I., Vázquez, E., Villaverde, A., Mangues, R., Eritja, R. ChemistryOpen, 8, 382-387 (2019).

“The small interfering RNAs (siRNAs) in cancer therapy: nano-based approach” Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C.D., Memari, F., Miri, S.R., Rad, M.R., Marmari, V. Int. J. Nanomedicine, 14, 3111-3128 (2019).

“The origins and the biological consequences of the Pur/Pyr DNA•RNA asymmetry” Terrazas, M., Genna, V., Portella, G., Villegas, N., Sánchez, D., Arnan, C., Pulido-Quetglas, C., Johnson, E., Guigó, R., Brun-Heath, I., Aviñó, A., Eritja, R., Orozco, M. Chem., 5, 1619-1631 (2019).

“On the race for more stretchable and tough hydrogels” Grijalvo, S., Eritja, R., Díaz Díaz, D. Gels, 5, 24 (2019).

“Gene delivery to the rat retina by non-viral vectors based on chloroquine-containing cationic niosomes” Mashal, M., Attia, N., Martínez-Navarrete, G., Soto-Sánchez, C., Fernández, E., Grijalvo, S., Eritja, R., Puras, G., Pedraz, J.L. J. Control. Rel., 304, 181-190 (2019).

“Study of conformational transitions of i-motif DNA using time-resolved fluorescence and multivariate analysis methods” Benabou, S., Ruckebusch, C., Sliwa, M., Aviñó, A., Eritja, R., Gargallo, R., de Juan, A.  Nucleic Acids Res., 47, 6590-6605 (2019).

“Expanding the limits of amide-triazole isosteric substitution in bisamide-based physical gels” Tautz, M., Torras, J., Grijalvo, S., Eritja, R., Saldías, C., Alemán, C., Díaz Díaz D. RSC Adv., 9, 20841-20851 (2019).

“Aptamer-peptide conjugates as a new strategy to modulate human α-thrombin binding affinity” Aviñó, A., Jorge, A.F., Huertas, C.S., Cova, T.F.G.G., Pais, A., Lechuga, L.M., Eritja, R., Fàbrega, C. Biochim. Biophys. Acta (General subjects), 1863, 1610-1630 (2019).

“Cationic niosome-based hBMP7 gene transfection of neuronal precursor NT2 cells to reduce the migration of glioma cells in vitro” Attia, N., Mashal, M., Grijalvo, S., Eritja, R., Puras, G., Pedraz, J.L. J. Drug Delivery Science Technol., 53, 101219 (2019).

“Stabilization of c-KIT G-quadruplex DNA structures by the RNA polymerase I inhibitors BMH-21 and BA-41” Mazzini, S., Gargallo, R., Musso, L., De Santis, F., Aviñó, A., Scaglioni, L., Eritja, R., Di Nicola, M., Zunino, F., Amatulli, A., Dallavalle, S. Int. J. Mol. Sci., 20, 4927 (2019).

“Alginate hydrogels as scaffolds and delivery systems to repair the damaged spinal cord” Grijalvo, S., Nieto-Díaz, M., Maza, R.M., Eritja, R., Díaz Díaz, D. Biotech J., 14, e1900275 (2019).

“A pH-dependent bolt involving cytosine bases located in the lateral loops of antiparallel G-quadruplex structures within the SMARCA4 gene promotor” Benabou S., Mazzini, S., Aviñó, A., Eritja, R. Gargallo, R. Sci. Rep., 9, 15807 (2019).

2018

Selective depletion of metastatic stem cells as therapy for human colorectal cancer. Céspedes, M.V., Unzueta, U., Aviñó, A., Gallardo, A., Álamo, P., Sala, R., Sánchez-Sardi, A., Casanova, I., Mangues, M.A., Lopez-Pousa, A., Eritja, R., Villaverde, A., Vázquez, E., Mangues, R. EMBO Mol. Med., 10, e8772 (2018).

DNA-based nanoscaffolds as vehicles for 5-fluoro-2’-deoxyuridine oligomers in colorectal cancer therapy. Jorge, A.F., Aviñó, A., Pais, A.A.C.C., Eritja, R., Fàbrega, C. Nanoscale, 10, 7238-7249 (2018).

Exploring PAZ/3’-overhang interaction to improve siRNA specificity. A combined experimental and modeling study. Alagia, A., Jorge, A.F., Aviño, A., Cova, T.F.G.G., Crehuet, R., Grijalvo, S., Alberto Pais, A.A.C.C., Eritja, R. Chem. Sci., 9, 2074-2086 (2018).

DNA origami-driven lithography for patterning on gold surfaces with sub-10 nanometer resolution. Gállego, I., Manning, B., Prades, J.D., Mir, M., Samitier, J., Eritja, R. Adv. Mat., 29, 1603233 (2017).

Glucose-nucleobase pseudo base pairs as a new biomolecular interaction in a DNA context. Vengut-Climent, E., Gómez-Pinto, I., Lucas, R., Peñalver, P., Aviñó, A., Fonseca-Guerra, C, Bickelhaupt, F.M.., Eritja, R., González, C., Morales, J.C. Angew. Chem. Int. Ed. Engl., 55, 8643-8647 (2016).

News U29

27 Feb

New method for the detection of RNA viruses such as SARS-CoV-2

Several CIBER-BBN groups at the University of Barcelona, the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC) and the Institute of Nanoscience and Materials of Aragon (INMA) —a joint institute of the CSIC and the University of Zaragoza (UNIZAR)— have developed a new method for detecting RNA viruses based on the technology of using probes that form triplex structures. This innovative methodology opens up new options to detect viruses such as SARS-CoV-2, the influenza A (H1N1) virus or the respiratory syncytial virus (RSV), a pathogen that affects newborns and requires differential diagnostic care. This[...]

15 Nov

Happy Day of Chemistry! The role of Chemistry in a sustainable research in health

Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

03 May

OPEN SUBMISSION FOR JOURNAL SPECIAL ISSUE ON OLIGONUCLEOTIDE BASED THERAPIES

Dr. Ramon Eritja, Scientific Director of NANBIOSIS unit 29 of Oligonucleotide Synthesis Platform (OSP) and Dr. Santiago Grijalvo researcher at NANBIOSIS unit 12 of Nanostructured liquid characterization, from CIBER-BBN and IQAC-CSIC, together with Dr. Andreia F. Jorge, from Coimbra Chemistry Centre (CQC), acting as guest editors of journal Pharmaceutics, of MDPI Publisher, welcome authors to submit their articles on special issues on Recent Trends in Oligonucleotide Based Therapies. In the past few decades, significant efforts have been made towards the clinical application of oligonucleotides. However, the potential of the therapeutic applications of RNA-based strategies have recently been spotlighted after the first approval of mRNA vaccines in response to COVID-19[...]

02 May

Wide representation of NANBIOSIS research in NALS 2022 and best Oral Presentation to Eloi Parladé

During the last 27-29 April, the 3rd International Conference on Nanomaterials Applied to Life Sciences 2022 (NALS 2022) has taken place in the Excellence Campus of Universidad de Cantabria in Santander (Spain), organized by the University of Cantabria and Institute Valdecilla-IDIVAL. NALS 2022 has been a multidisciplinary conference series sharing new results and ideas in the fields of biosensors, lab on a chip, drug delivery nanopharmacy. nanobiotechnology, intelligent nanomaterials, magnetic materials, nanotoxicity, antimicrobials, novel applications of 3d bioprinting and nanoimaging. NANBIOSIS has been represented at this edition by members of several of its units, among them we must highlight the set of four ora[...]

27 Apr

OPEN SUBMISSION FOR FRONTIERS IN CHEMISTRY SPECIAL ISSUE ON NUCLEIC ACID-BASED APTAMERS IN THERAPEUTICS AND DIAGNOSTICS

Dr. Anna Aviñó, Scientific Coordianator of NANBIOSIS unit 29 of Oligonucleotide Synthesis Platform (OSP) and Dr. Carme Fàbrega from the Nucleic Acid Chemistry group from CIBER-BBN and IQAC_CSIC, together with Dr. Claudia Riccardi from the University of Naples Federico II, Dr. Stefania Mazzini from University of Milan, and Dr. Raimundo Gargallo from the University of Barcelona, acting as guest editors of the journal Frontiers in Chemistry, welcome authors to submit their articles on special issues on Nucleic Acid-Based Aptamers in Therapeutics and Diagnostics. Nucleic acid‐based aptamers are short DNA or RNA sequences able to adopt specific three‐dimensional architectures. The high affinity and selectivity shown for a selected target, as well as t[...]

21 Apr

The coming revolution: synthetic DNA and RNA for therapeutic and diagnostic applications

The discovery of the mRNA vaccines for the treatment of coronavirus, as well as new medicines for the treatment of genetic diseases, has been important in the quest of solutions for undrugable diseases in an unexpected short-time. Thus, the chemical modifications of nucleic acids with diagnostic and therapeutic purposes is now a reality, a revolution that promises to give hopes on unsolved medical problems or optimize previous approaches, largely due to the research push for the development of mRNA vaccines against SARS-CoV-2 infection. Now, the prestigious “The Chemical Record” journal has invited the Nucleic Acids Chemistry group, of IQAC-CSIC and[...]

10 Jan

U29.-Oligonucleotide-Synthesis-Platform
DNA nanotechnologists are in mourning

At the end of the XXth century Nanotechnology appeared as one of the more powerful technologies for the future. At that time material sciences were able to produce nanomaterials with exquisite size control and atomic force, microscopy was able to visualize objects in the nanoscale and photolithography arrived to their physical limits in the preparation of computer chips threatening Moore’s law. This empirical law saying that as transistor components shrank, the number per chip doubled about every 18 months, was acting from 1971  (Intel’s first chip) to billions in the present times.  At these times, one crucial development was t[...]

U29. Oligonucleotide Synthesis Platform
• Read More